Edwards Lifesciences Corp — Director's Dealing 2021

Nov 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edwards Lifesciences Corp (EW)
CIK: 0001099800
Period of Report: 2021-11-05

Reporting Person: BOBO DONALD E JR (CVP,Strategy/Corp Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-05	Common Stock	M	11050.0000	$21.7600	Acquired	67449.3995	Direct
2021-11-05	Common Stock	S	4591.0000	$117.6789	Disposed	62858.3995	Direct
2021-11-05	Common Stock	S	6459.0000	$116.8051	Disposed	56399.3995	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-05	Employee Stock Option (Right to Acquire)	$21.7600	M	11050.0000	Disposed	2022-05-13	Common Stock (11050.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	38157.8315	Indirect
Common Stock	123820.0000	Indirect

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 1, 2021.

F2: This transaction was executed in multiple trades at prices ranging from $117.42 to $118.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $116.40 to $117.36. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.